Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.

Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Grøn R, Halladin N, Jodar E

Diabetes care26 Feb 2018Cited by 142 (Europe PMC)

PMID29483185DOI10.2337/dc17-1114PepBankPUB-29483185

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, IDegLira (insulin degludec/liraglutide) lowered HbA1c to 6.7% and was noninferior to basal-bolus insulin.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination lowered HbA1c about as much as basal-bolus insulin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Estimated treatment difference
−0.02%
IDegLira vs basal-bolus
Source sentences
Summary
Glycated hemoglobin (HbA_1c) decreased from 8.2% (66 mmol/mol) to 6.7% (50 mmol/mol) with IDegLira and from 8.2% (67 mmol/mol) to 6.7% (50 mmol/mol) with basal-bolus (estimated treatment difference [ETD] -0.02% [95% CI -0.16, 0.12]; -0.2 mmol/mol [95% CI -1.7, 1.3]), confirming IDegLira no…
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318501
02HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, IDegLira gave fewer severe or confirmed symptomatic hypoglycemia events than basal-bolus insulin.
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination caused fewer low blood sugar events than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseSevere or blood glucose-confirmed symptomatic hypoglycemia events
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Adverse events · Metabolic and weight
Measurements
Risk ratio
0.39 ratio
IDegLira vs basal-bolus
Rate ratio
0.11 ratio
IDegLira vs basal-bolus
Source sentences
Summary
The number of severe or blood glucose-confirmed symptomatic hypoglycemia events was lower with IDegLira versus basal-bolus (risk ratio 0.39 [95% CI 0.29, 0.51]; rate ratio 0.11 [95% CI 0.08, 0.17]).
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318502
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, body weight decreased with IDegLira and increased with basal-bolus insulin.
In plain wordsIn adults with type 2 diabetes, weight fell with the insulin degludec/liraglutide combination and rose with basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Body weight · Metabolic and weight
Measurements
Estimated treatment difference
−3.6 kg
IDegLira vs basal-bolus
Source sentences
Summary
Body weight decreased with IDegLira and increased with basal-bolus (ETD -3.6 kg [95% CI -4.2, -2.9]).
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318503
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, fasting plasma glucose reductions were similar with IDegLira and basal-bolus insulin.
In plain wordsIn adults with type 2 diabetes, fasting blood glucose fell by a similar amount with the insulin degludec/liraglutide combination and basal-bolus insulin.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose reduction
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Fasting plasma glucose reductions were similar
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318504
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, lunch, dinner and bedtime self-monitored plasma glucose was significantly higher with IDegLira than with basal-bolus insulin.
In plain wordsIn adults with type 2 diabetes, self-checked blood glucose at lunch, dinner and bedtime was higher with the insulin degludec/liraglutide combination than with basal-bolus insulin.
Peptide
Liraglutide
Outcome
IncreaseSelf-monitored plasma glucose at lunch, dinner and bedtime
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
lunch, dinner, and bedtime self-monitored plasma glucose measurements were significantly lower with basal-bolus.
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318505
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, 66% on IDegLira and 67.0% on basal-bolus insulin reached HbA1c below 7.0%.
In plain wordsIn adults with type 2 diabetes, a similar share reached the HbA1c target with the insulin degludec/liraglutide combination and with basal-bolus insulin.
Peptide
Liraglutide
Outcome
No significant changeProportion reaching HbA1c below 7.0%
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Patients with HbA1c <7.0%
66%
IDegLira
Patients with HbA1c <7.0%
67%
basal-bolus
Source sentences
Summary
Sixty-six percent of patients on IDegLira vs. 67.0% on basal-bolus achieved HbA_1c <7.0% (53 mmol/mol).
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318506
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes uncontrolled on basal insulin and metformin, total daily insulin dose was lower with IDegLira (40 units) than with basal-bolus insulin (84 units).
In plain wordsIn adults with type 2 diabetes, the insulin degludec/liraglutide combination needed a lower total daily insulin dose than basal-bolus insulin.
Peptide
Liraglutide
Outcome
DecreaseTotal daily insulin dose
Study
n: not reported in source
Comparator
Basal-bolus insulin (IGlar U100 plus insulin aspart)
Outcome group
Glycemic control · Metabolic and weight
Measurements
Total daily insulin dose
40 units
IDegLira
Total daily insulin dose
84 units
basal-bolus
Source sentences
Summary
Total daily insulin dose was lower with IDegLira (40 units) than basal-bolus (84 units total; 52 units basal).
1 context sentence(design, population, supporting numbers)
Summary · context
A phase 3b trial examined patients with uncontrolled type 2 diabetes on insulin glargine (IGlar U100) 20-50 units/day and metformin, randomized to IDegLira or IGlar U100 and insulin aspart ≤4 times per day.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2948318507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02420262

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 50626 Jul 2015 to 5 Oct 2016

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 29 Mar 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.